Lexaria receives patents for antiviral drug delivery, epilepsy treatment

Lexaria Bioscience announces three new patent awards. In the European Union, the Company has received a new granted patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This is the Company’s second granted patent in this patent family with an earlier patent granted in Canada. This patent will expire in 2039, if not extended and was validated in the following countries: Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain, Sweden and Switzerland. In Canada, Lexaria has received a new granted patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is the Company’s fourth granted patent in this patent family which was previously granted in the US, Australia, and Japan. This patent will expire in 2041 if not extended. This patent builds on original research conducted by Lexaria in 2021 wherein the Company evidenced in animal studies that DehydraTECH processing of five different antiviral drugs belonging to three classes of drugs all were delivered into bloodstream at rates from 42% improvement to 204% improvement, compared to the same drugs not processed with DehydraTECH. Building on prior patent success in the US related to epilepsy, Lexaria has received its fourth granted US patent in patent family #24, Compositions and Methods for Treating Epilepsy. This patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex(R). This patent will expire in 2044 if not extended. With the issuance of these three new patents, Lexaria’s patent portfolio has now grown to 46 granted patents worldwide. Lexaria’s intellectual property remains a significant component in supporting future business objectives.